Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.12
+0.21 (0.84%)
At close: May 9, 2025, 4:00 PM
24.46
-0.66 (-2.63%)
After-hours: May 9, 2025, 4:07 PM EDT
Pacira BioSciences Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Pacira BioSciences stock ranges from a low of $10 to a high of $65. The average price target of $29.89 forecasts a 18.99% increase in the stock price over the next year.
Price Target: $29.89 (+18.99%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 3 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +19.43% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +27.39% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +158.76% | Apr 8, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | -4.46% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +27.39% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
767.42M
from 700.97M
Increased by 9.48%
Revenue Next Year
854.19M
from 767.42M
Increased by 11.31%
EPS This Year
2.96
from -2.15
EPS Next Year
3.72
from 2.96
Increased by 25.64%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 813.7M | 966.5M | 1.1B | ||
| Avg | 767.4M | 854.2M | 940.3M | ||
| Low | 725.2M | 769.8M | 798.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.1% | 25.9% | 27.0% | ||
| Avg | 9.5% | 11.3% | 10.1% | ||
| Low | 3.5% | 0.3% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.54 | 4.74 | 6.28 | ||
| Avg | 2.96 | 3.72 | 4.64 | ||
| Low | 2.47 | 2.73 | 3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 60.2% | 68.8% | ||
| Avg | - | 25.6% | 24.9% | ||
| Low | - | -7.6% | -17.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.